-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Royalty Pharma plc quarterly/annual Operating Income (Loss) history and growth rate from Q2 2019 to Q4 2024.
- Royalty Pharma plc Operating Income (Loss) for the quarter ending December 31, 2024 was $362M, a 41% decline year-over-year.
- Royalty Pharma plc Operating Income (Loss) for the twelve months ending December 31, 2024 was $1.29B, a 13.4% decline year-over-year.
- Royalty Pharma plc annual Operating Income (Loss) for 2024 was $1.29B, a 13.4% decline from 2023.
- Royalty Pharma plc annual Operating Income (Loss) for 2023 was $1.49B, a 386% increase from 2022.
- Royalty Pharma plc annual Operating Income (Loss) for 2022 was $307M, a 78.5% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)